Results 151 to 160 of about 304,634 (351)

Studying the effect of hyperoside on recovery from cyclophosphamide induced oligoasthenozoospermia

, 2023
Qigang Fan, Ruifen He, Yi Li, Pu Gao, Runchun Huang, Rong Li, Jiayu Zhang, Hongli Li, Xiaolei Liang   +8 more
openalex   +2 more sources

Basiliximab in the Prophylaxis of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: A Prospective, Multicenter, Open‐Label, Randomized Controlled Study

American Journal of Hematology, EarlyView.
Zhenbin Wei, Rongrong Liu, Lingling Shi, Qiaochuan Li, Lianjin Liu, Baoshi Zheng, Chunjie Qin, Hong Chen, Guyun Wang, Meiqing Wu, Gaohui Yang, Ruolin Li, Zhaoping Gan, Qi Zhou, Jing Fan, Xuemei Zhou, Yinghua Chen, Zhiyu Zeng, Zhongming Zhang, Yongrong Lai   +19 more
wiley   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide

, 1989
Eli Kedar, Revital Ben-Aziz, Eyal Epstein, Benny Leshem   +3 more
openalex   +2 more sources

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

Arthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators   +10 more
wiley   +1 more source

Incidence and Clinical Characteristics of Oral Mucositis in Allogeneic Hematopoietic Stem Cell Transplantation with Post-transplant Cyclophosphamide Treatment [PDF]

, 2021
Susu Gong, Hong Xiao, Xiaofang Ding, Kaitai Yang, Jian Hu, Yajing Xu, Bin Fu   +6 more
openalex   +1 more source

Long‐Term Outcomes of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Systemic Sclerosis Patients with Impaired Cardiac Function

Arthritis &Rheumatology, Accepted Article.
Objective High intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced SSc. The role of reduced intensity conditioning (RIC) prior to AHSCT in this population remains unclear. We conducted this study to determine the long‐term outcomes of RIC AHSCT in SSc patients with cardiac ...
Yonatan Lean, Carrie Richardson, Anthony Esposito, Katy Bedjeti, George E. Georges   +4 more
wiley   +1 more source

Deciphering the anti-angiogenic effect of endostatin/cyclophosphamide to normalize tumor micrangium through notch signaling pathway in colon cancer [PDF]

, 2015
Jinyan Lv, Tai-Yuan Hu, Ruoyu Wang, Jinming Zhu, Gang Wang   +4 more
openalex   +1 more source

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

Arthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner [PDF]

, 2023
Ekaterina Kachur, Jai N. Patel, Allison Morse, Donald C. Moore, Justin Arnall   +4 more
openalex   +1 more source